<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="187219">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00656487</url>
  </required_header>
  <id_info>
    <org_study_id>DA024194</org_study_id>
    <secondary_id>DA024194</secondary_id>
    <nct_id>NCT00656487</nct_id>
  </id_info>
  <brief_title>Neurobiology of Cannabis Dependence</brief_title>
  <acronym>SCCAN</acronym>
  <official_title>Neurobiology of Cannabis Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Scripps Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Scripps Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out more about cognitive functioning in people who are
      cannabis dependent, relative to people who do not use cannabis, and how their brains process
      information after one month of not using cannabis. An additional goal is to characterize the
      severity of cannabis dependence using precipitated and naturalistic withdrawal with a double
      blind, placebo controlled, single administration of rimonabant. Research assessments occur
      bi-weekly throughout this 28 day study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to find out more about cognitive functioning in people who are
      cannabis dependent, relative to people who do not use cannabis, and how their brains process
      information after one month of not using cannabis. An additional goal is to characterize the
      severity of cannabis dependence using precipitated and naturalistic withdrawal with a double
      blind, placebo controlled, single administration of rimonabant. Research assessments occur
      bi-weekly throughout this 28 day study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cannabis Withdrawal</measure>
    <time_frame>2 times per week for 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuroendocrine and monoamine assays</measure>
    <time_frame>2 times over 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropsychological performance</measure>
    <time_frame>baseline and final study visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI</measure>
    <time_frame>baseline and final visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>1 time per week for 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>1 time per week for 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Craving</measure>
    <time_frame>2 times per week for 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cannabis Dependence</condition>
  <condition>Cannabis Withdrawal</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabis dependent/rimonabant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabis dependent/placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-using controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rimonabant</intervention_name>
    <description>double blind, placebo controlled, single dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>CB1 receptor antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Cannabis Dependent Subjects:

        Inclusion Criteria:

          -  males or females 21-30 years of age

          -  meets DSM-IV diagnosis of Cannabis Dependence

          -  willing to be abstinent for 28 days during study

          -  smokes &lt; 10 cigarettes per day

          -  drinks &lt; 1 (female) or &lt; 2 (male) per day

          -  high school diploma recipient

          -  English native language

        Exclusion Criteria:

          -  active suicide ideation

          -  meets DSM-IV diagnosis for dependence on other substances other than cannabis

          -  use of hallucinogens in the past year

          -  significant medical disorders

          -  pregnant women

          -  meets DSM-IV diagnosis for a major Axis I disorder other than cannabis dependence,
             including mood or anxiety disorders

          -  currently taking psychoactive medication

          -  history of neurological disorder

          -  left-handed

          -  color blindness or non correctable vision or hearing problems

          -  claustrophobic

          -  non-removable metal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara J Mason, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Scripps Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Scripps Research Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 19, 2012</lastchanged_date>
  <firstreceived_date>April 7, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Scripps Research Institute</investigator_affiliation>
    <investigator_full_name>Barbara J. Mason</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Cannabis Dependence</keyword>
  <keyword>Marijuana Dependence</keyword>
  <keyword>Cannabis Withdrawal</keyword>
  <keyword>Rimonabant</keyword>
  <keyword>CB1 receptor antagonist</keyword>
  <keyword>Neuropsychology</keyword>
  <keyword>fMRI</keyword>
  <keyword>Endocannabinoids</keyword>
  <keyword>Cortisol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
